BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has earned a consensus rating of “Buy” from the seven ratings firms that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $4.30.

A number of equities research analysts recently weighed in on the company. Cantor Fitzgerald reissued a “buy” rating and set a $4.50 target price on shares of BioDelivery Sciences International in a research report on Thursday, August 9th. Zacks Investment Research raised BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $3.25 target price on the stock in a research report on Monday, July 23rd. HC Wainwright decreased their target price on BioDelivery Sciences International from $4.00 to $3.50 and set a “buy” rating on the stock in a research report on Wednesday, May 23rd. Finally, ValuEngine raised BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research report on Friday, June 1st.

Shares of NASDAQ:BDSI traded down $0.10 during midday trading on Wednesday, hitting $2.85. The company’s stock had a trading volume of 3,810 shares, compared to its average volume of 418,050. The company has a market cap of $175.70 million, a P/E ratio of -7.35 and a beta of 0.63. BioDelivery Sciences International has a fifty-two week low of $1.70 and a fifty-two week high of $3.20. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.90 and a current ratio of 3.16.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings results on Thursday, August 9th. The specialty pharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.18) by $0.02. The company had revenue of $12.18 million for the quarter, compared to the consensus estimate of $12.44 million. BioDelivery Sciences International had a negative return on equity of 278.79% and a negative net margin of 103.01%. equities analysts predict that BioDelivery Sciences International will post -0.63 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. acquired a new stake in BioDelivery Sciences International during the second quarter worth about $1,770,000. Renaissance Technologies LLC boosted its holdings in BioDelivery Sciences International by 214.7% during the second quarter. Renaissance Technologies LLC now owns 166,779 shares of the specialty pharmaceutical company’s stock valued at $492,000 after purchasing an additional 113,779 shares in the last quarter. Cortina Asset Management LLC acquired a new stake in BioDelivery Sciences International during the second quarter valued at approximately $5,629,000. PNC Financial Services Group Inc. acquired a new stake in BioDelivery Sciences International during the second quarter valued at approximately $148,000. Finally, BlackRock Inc. boosted its holdings in BioDelivery Sciences International by 2.7% during the second quarter. BlackRock Inc. now owns 1,190,286 shares of the specialty pharmaceutical company’s stock valued at $3,512,000 after purchasing an additional 30,991 shares in the last quarter. 45.50% of the stock is currently owned by institutional investors and hedge funds.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Recommended Story: What are the most popular ETFs

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.